RxDoctor Payments Data

Danielle Lee

Psychiatric/Mental Health · Montgomery, ALNPI 1679114532

Payments from drug & device makers

$489in general payments, 2019–2025

Across 27 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$113
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$99
  • AbbVie$63
  • Otsuka America Pharmaceutical, Inc.$58
  • Alkermes, Inc.$39
  • Johnson & Johnson Surgical Vision, Inc.$37
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$44290%
  • Education$4710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$489 in reported general payments places this provider in the 35th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$1,711
Medicare patients
16
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate121$344,256
IngrezzaValbenazine Tosylate11$98,152
Abilify MaintenaAripiprazole14$41,759
AristadaAripiprazole Lauroxil12$28,796
PerserisRisperidone11$26,068
Haloperidol Decanoate204$7,850
Fluphenazine Decanoate63$7,315
SeroquelQuetiapine Fumarate15$5,952
Haloperidol129$5,061
Benztropine Mesylate226$4,799
Fluphenazine Hcl21$4,226
Trazodone Hcl211$3,325
Ziprasidone Hcl23$3,240
Divalproex Sodium128$2,418
Aripiprazole42$2,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$113$344,256121 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$58$41,75914 claims
Alkermes, Inc.Aristada$39$28,79612 claims
Indivior Inc.Perseris$30$26,06811 claims
Lilly USA, LLCOlanzapine$17$1,59367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →